Frovatriptan 2.5mg plus dexketoprofen (25mg or 37.5 mg) in menstrually related migraine. Subanalysis from a double-blind, randomized trial

G. Allais; G. Bussone; V. Tullo; P. Cortelli; F. Valguarnera; P. Barbanti; G. Sette; F. D'Onofrio; M. Curone; C. Benedetto

doi:10.1177/0333102414542290

Frovatriptan 2.5mg plus dexketoprofen (25mg or 37.5 mg) in menstrually related migraine. Subanalysis from a double-blind, randomized trial

G. Allais, G. Bussone, V. Tullo, P. Cortelli, F. Valguarnera, P. Barbanti, G. Sette, F. D'Onofrio, M. Curone, C. Benedetto

Research output: Contribution to journal › Article › peer-review

Abstract

Purpose: The purpose of this article is to investigate the efficacy and safety of frovatriptan plus dexketoprofen 25 or 37.5 mg (FroDex25 or FroDex37.5, respectively) compared to that of frovatriptan 2.5 mg (Frova) in menstrually related migraine (MRM). Aim: The aim of this article is to analyze a subgroup of 76 women who treated an MRM attack in this multicenter, randomized, double-blind, parallel-group study. Methods: The primary end-point was the proportion of patients who were pain free (PF) at two hours. Secondary endpoints included pain-relief (PR) at two hours and 48 hours sustained pain free (SPF). Results: PF rates at two hours were 29% under Frova, 48% under FroDex25 and 64% under FroDex37.5 (p

Original language	English
Pages (from-to)	45-50
Number of pages	6
Journal	Cephalalgia
Volume	35
Issue number	1
DOIs	https://doi.org/10.1177/0333102414542290
Publication status	Published - 2015

Keywords

Dexketoprofen
Frovatriptan
Menstrually related migraine
Migraine attacks

ASJC Scopus subject areas

Clinical Neurology

Access to Document

10.1177/0333102414542290

Cite this

@article{6bbfec5ac17448899978e4717b7bce62,

title = "Frovatriptan 2.5mg plus dexketoprofen (25mg or 37.5 mg) in menstrually related migraine. Subanalysis from a double-blind, randomized trial",

abstract = "Purpose: The purpose of this article is to investigate the efficacy and safety of frovatriptan plus dexketoprofen 25 or 37.5 mg (FroDex25 or FroDex37.5, respectively) compared to that of frovatriptan 2.5 mg (Frova) in menstrually related migraine (MRM). Aim: The aim of this article is to analyze a subgroup of 76 women who treated an MRM attack in this multicenter, randomized, double-blind, parallel-group study. Methods: The primary end-point was the proportion of patients who were pain free (PF) at two hours. Secondary endpoints included pain-relief (PR) at two hours and 48 hours sustained pain free (SPF). Results: PF rates at two hours were 29% under Frova, 48% under FroDex25 and 64% under FroDex37.5 (p",

keywords = "Dexketoprofen, Frovatriptan, Menstrually related migraine, Migraine attacks",

author = "G. Allais and G. Bussone and V. Tullo and P. Cortelli and F. Valguarnera and P. Barbanti and G. Sette and F. D'Onofrio and M. Curone and C. Benedetto",

year = "2015",

doi = "10.1177/0333102414542290",

language = "English",

volume = "35",

pages = "45--50",

journal = "Cephalalgia",

issn = "0333-1024",

publisher = "SAGE Publications Ltd",

number = "1",

}

TY - JOUR

T1 - Frovatriptan 2.5mg plus dexketoprofen (25mg or 37.5 mg) in menstrually related migraine. Subanalysis from a double-blind, randomized trial

AU - Allais, G.

AU - Bussone, G.

AU - Tullo, V.

AU - Cortelli, P.

AU - Valguarnera, F.

AU - Barbanti, P.

AU - Sette, G.

AU - D'Onofrio, F.

AU - Curone, M.

AU - Benedetto, C.

PY - 2015

Y1 - 2015

N2 - Purpose: The purpose of this article is to investigate the efficacy and safety of frovatriptan plus dexketoprofen 25 or 37.5 mg (FroDex25 or FroDex37.5, respectively) compared to that of frovatriptan 2.5 mg (Frova) in menstrually related migraine (MRM). Aim: The aim of this article is to analyze a subgroup of 76 women who treated an MRM attack in this multicenter, randomized, double-blind, parallel-group study. Methods: The primary end-point was the proportion of patients who were pain free (PF) at two hours. Secondary endpoints included pain-relief (PR) at two hours and 48 hours sustained pain free (SPF). Results: PF rates at two hours were 29% under Frova, 48% under FroDex25 and 64% under FroDex37.5 (p

AB - Purpose: The purpose of this article is to investigate the efficacy and safety of frovatriptan plus dexketoprofen 25 or 37.5 mg (FroDex25 or FroDex37.5, respectively) compared to that of frovatriptan 2.5 mg (Frova) in menstrually related migraine (MRM). Aim: The aim of this article is to analyze a subgroup of 76 women who treated an MRM attack in this multicenter, randomized, double-blind, parallel-group study. Methods: The primary end-point was the proportion of patients who were pain free (PF) at two hours. Secondary endpoints included pain-relief (PR) at two hours and 48 hours sustained pain free (SPF). Results: PF rates at two hours were 29% under Frova, 48% under FroDex25 and 64% under FroDex37.5 (p

KW - Dexketoprofen

KW - Frovatriptan

KW - Menstrually related migraine

KW - Migraine attacks

UR - http://www.scopus.com/inward/record.url?scp=84927749133&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84927749133&partnerID=8YFLogxK

U2 - 10.1177/0333102414542290

DO - 10.1177/0333102414542290

M3 - Article

C2 - 25053749

AN - SCOPUS:84927749133

VL - 35

SP - 45

EP - 50

JO - Cephalalgia

JF - Cephalalgia

SN - 0333-1024

IS - 1

ER -

Frovatriptan 2.5mg plus dexketoprofen (25mg or 37.5 mg) in menstrually related migraine. Subanalysis from a double-blind, randomized trial

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this